Patient Enrollment Begins In Third And Final Cohort Of The Phase 2 MATRICS-1 Clinical Study Evaluating Athersys' MultiStem Following Hemorrhagic Trauma
Portfolio Pulse from Happy Mohamed
Athersys, Inc. has begun patient enrollment in the third and final cohort of the Phase 2 MATRICS-1 clinical study evaluating MultiStem in patients following resuscitation from hemorrhagic trauma. The study is conducted at UTHealth Houston and Memorial Hermann-Texas Medical Center, with support from MTEC and the Department of Defense.
June 01, 2023 | 8:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Athersys has started patient enrollment in the final cohort of the Phase 2 MATRICS-1 clinical study for MultiStem therapy, potentially bringing the company closer to a new treatment for hemorrhagic trauma patients.
The initiation of the final cohort in the Phase 2 MATRICS-1 clinical study is a significant milestone for Athersys, as it brings the company closer to potentially having a new treatment for hemorrhagic trauma patients. Positive results from this study could lead to increased investor interest and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100